Mirtazapin

Mirtazapin
(IUPAC) ime
	(±)-2-metil-1,2,3,4,10,14b-heksahidropirazino[2,1-a]pirido[2,3-c][2]benzazepin
Klinički podaci
Robne marke	Remeron, Avanza, Zispin
AHFS/Drugs.com	Monografija
MedlinePlus	a697009
Identifikatori
CAS broj	61337-67-5
ATC kod	N06AX11
PubChem	4205
DrugBank	DB00370
ChemSpider	4060
UNII	A051Q2099Q
KEGG	D00563
ChEBI	CHEBI:6950
ChEMBL	CHEMBL654
Hemijski podaci
Formula	C17H19N3
Mol. masa	265,35 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C17H19N3/c1-19-9-10-20-16(12-19)15-7-3-2-5-13(15)11-14-6-4-8-18-17(14)20/h2-8,16H,9-12H2,1H3 ; Key: RONZAEMNMFQXRA-UHFFFAOYSA-N
Sinonimi	6-Azamianserin, Org 3770
Fizički podaci
Gustina	1,22 g/cm³
Tačka topljenja	114–116 °C (237–241 °F)
Tačka ključanja	432 °C (810 °F)
Rastvorljivost u voda	Rastvoran u metanolu i hloroformu mg/mL (20 °C)
Farmakokinetički podaci
Bioraspoloživost	50%
Vezivanje za proteine plazme	85%
Metabolizam	Hepatički (CYP1A2, CYP2D6, i CYP3A4)
Poluvreme eliminacije	20–40 sata
Izlučivanje	Urin (75%); Izmet (15%)
Farmakoinformacioni podaci
Trudnoća	?
Pravni status	℞ Prescription only
Način primene	Oralno

Mirtazapin (Remeron, Avanza, Zispin) je noradrenergički i specifični serotonergički antidepresiv (NaSSA) koji je razvila kompanija Organon International u Sjedinjenim Državama 1990. godine. On se prvenstveno koristi za lečenje depresije. On isto takao nalazi primenu kao anksiolitik, hipnotik, antiemetik i stimulant apetita. On je strukturno sličan sa mianserinom, i klasifikuje se kao tetraciklični antidepresant (TeCA).

Medicinska upotreba

Mirtazapin se prvenstveno koristi za tretiranje kliničke depresije i drugih poremećaja raspoloženja.^[8]^[9]

On isto tako može da bude koristan u tretiranju sledećih oboljenja, mada nije odobren za te primene:

Reference

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit
↑ Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.
↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit
↑ ^6,0 ^6,1 ^6,2 ^6,3 ^6,4 ^6,5 Timmer CJ, Sitsen JM, Delbressine LP (June 2000). „Clinical pharmacokinetics of mirtazapine”. Clinical Pharmacokinetics 38 (6): 461–74. DOI:10.2165/00003088-200038060-00001. PMID 10885584.
↑ ^7,0 ^7,1 Anttila SA, Leinonen EV (2001). „A review of the pharmacological and clinical profile of mirtazapine”. CNS Drug Reviews 7 (3): 249–64. DOI:10.1111/j.1527-3458.2001.tb00198.x. PMID 11607047.
↑ Gorman JM (1999). „Mirtazapine: clinical overview”. J Clin Psychiatry 60 Suppl 17: 9–13; discussion 46–8. PMID 10446735.
↑ Benjamin S, Doraiswamy PM (July 2011). „Review of the use of mirtazapine in the treatment of depression”. Expert Opinion on Pharmacotherapy 12 (10): 1623–32. DOI:10.1517/14656566.2011.585459. PMID 21644844.
↑ Goodnick PJ, Puig A, DeVane CL, Freund BV (July 1999). „Mirtazapine in major depression with comorbid generalized anxiety disorder”. J Clin Psychiatry 60 (7): 446–8. DOI:10.4088/JCP.v60n0705. PMID 10453798.
↑ ^11,0 ^11,1 ^11,2 ^11,3 Croom KF, Perry CM, Plosker GL (2009). „Mirtazapine: a review of its use in major depression and other psychiatric disorders”. CNS Drugs 23 (5): 427–52. DOI:10.2165/00023210-200923050-00006. PMID 19453203.
↑ Muehlbacher M, Nickel MK, Nickel C, et al. (December 2005). „Mirtazapine treatment of social phobia in women: a randomized, double-blind, placebo-controlled study”. Journal of Clinical Psychopharmacology 25 (6): 580–3. DOI:10.1097/01.jcp.0000186871.04984.8d. PMID 16282842. Arhivirano iz originala na datum 2015-11-27. Pristupljeno 2014-04-05.
↑ Koran LM, Quirk T, Lorberbaum JP, Elliott M (October 2001). „Mirtazapine treatment of obsessive-compulsive disorder”. J Clin Psychopharmacol 21 (5): 537–9. DOI:10.1097/00004714-200110000-00016. PMID 11593084.
↑ Carpenter LL, Leon Z, Yasmin S, Price LH (June 1999). „Clinical experience with mirtazapine in the treatment of panic disorder”. Ann Clin Psychiatry 11 (2): 81–6. DOI:10.3109/10401239909147053. PMID 10440525.
↑ Carli V, Sarchiapone M, Camardese G, Romano L, DeRisio S (July 2002). „Mirtazapine in the treatment of panic disorder”. Arch. Gen. Psychiatry 59 (7): 661–2. DOI:10.1001/archpsyc.59.7.661. PMID 12090820.
↑ Hrdlicka M, Beranova I, Zamecnikova R, Urbanek T (April 2008). „Mirtazapine in the treatment of adolescent anorexia nervosa. Case-control study”. European Child & Adolescent Psychiatry 17 (3): 187–9. DOI:10.1007/s00787-007-0670-8. PMID 18357426.
↑ Hartmann PM (January 1999). „Mirtazapine: a newer antidepressant”. Am Fam Physician 59 (1): 159–61. PMID 9917581.
↑ Jindal RD (2009). „Insomnia in patients with depression: some pathophysiological and treatment considerations”. CNS Drugs 23 (4): 309–29. PMID 19374460.
↑ Nutt DJ (June 2002). „Tolerability and safety aspects of mirtazapine”. Human Psychopharmacology 17 Suppl 1: S37–41. DOI:10.1002/hup.388. PMID 12404669.
↑ ^20,0 ^20,1 Li TC, Shiah IS, Sun CJ, Tzang RF, Huang KC, Lee WK (June 2011). „Mirtazapine relieves post-electroconvulsive therapy headaches and nausea: a case series and review of the literature”. The Journal of ECT 27 (2): 165–7. DOI:10.1097/YCT.0b013e3181e63346. PMID 21602639. Arhivirano iz originala na datum 2013-05-09. Pristupljeno 2014-04-05.
↑ Kast RE, Foley KF (July 2007). „Cancer chemotherapy and cachexia: mirtazapine and olanzapine are 5-HT3 antagonists with good antinausea effects”. Eur J Cancer Care (Engl) 16 (4): 351–4. DOI:10.1111/j.1365-2354.2006.00760.x. PMID 17587360.
↑ Landowski J (2002). „[Mirtazapine--an antidepressant]” (Polish). Psychiatria Polska 36 (6 Suppl): 125–30. PMID 12647431.
↑ Chinuck RS, Fortnum H, Baldwin DR (December 2007). „Appetite stimulants in cystic fibrosis: a systematic review”. Journal of Human Nutrition and Dietetics : the Official Journal of the British Dietetic Association 20 (6): 526–37. DOI:10.1111/j.1365-277X.2007.00824.x. PMID 18001374.
↑ Davis MP, Khawam E, Pozuelo L, Lagman R (August 2002). „Management of symptoms associated with advanced cancer: olanzapine and mirtazapine. A World Health Organization project”. Expert Review of Anticancer Therapy 2 (4): 365–76. DOI:10.1586/14737140.2.4.365. PMID 12647979.
↑ Twycross R, Greaves MW, Handwerker H, et al. (January 2003). „Itch: scratching more than the surface”. QJM : Monthly Journal of the Association of Physicians 96 (1): 7–26. DOI:10.1093/qjmed/hcg002. PMID 12509645.
↑ Greaves MW (2005). „Itch in systemic disease: therapeutic options”. Dermatologic Therapy 18 (4): 323–7. DOI:10.1111/j.1529-8019.2005.00036.x. PMID 16297004.
↑ Colombo B, Annovazzi PO, Comi G (October 2004). „Therapy of primary headaches: the role of antidepressants”. Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 25 Suppl 3: S171–5. DOI:10.1007/s10072-004-0280-x. PMID 15549531.
↑ Tajti J, Almási J (June 2006). „[Effects of mirtazapine in patients with chronic tension-type headache. Literature review]” (Hungarian). Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakológiai Egyesület Lapja = Official Journal of the Hungarian Association of Psychopharmacology 8 (2): 67–72. PMID 17073214.

Literatura

Stimmel GL, Dopheide JA, Stahl SM (1997). „Mirtazapine: an antidepressant with noradrenergic and specific serotonergic effects”. Pharmacotherapy 17 (1): 10–21. PMID 9017762.
Anttila SA, Leinonen EV (2001). „A review of the pharmacological and clinical profile of mirtazapine”. CNS Drug Rev 7 (3): 249–64. DOI:10.1111/j.1527-3458.2001.tb00198.x. PMID 11607047.

Spoljašnje veze

	Portal Medicina
	Portal Hemija

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[3] Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit

[4] Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.

[5] Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit

[pmid10885584-6] 6,0 ^6,1 ^6,2 ^6,3 ^6,4 ^6,5 Timmer CJ, Sitsen JM, Delbressine LP (June 2000). „Clinical pharmacokinetics of mirtazapine”. Clinical Pharmacokinetics 38 (6): 461–74. DOI:10.2165/00003088-200038060-00001. PMID 10885584.

[pmid11607047-7] 7,0 ^7,1 Anttila SA, Leinonen EV (2001). „A review of the pharmacological and clinical profile of mirtazapine”. CNS Drug Reviews 7 (3): 249–64. DOI:10.1111/j.1527-3458.2001.tb00198.x. PMID 11607047.

[pmid10446735-8] Gorman JM (1999). „Mirtazapine: clinical overview”. J Clin Psychiatry 60 Suppl 17: 9–13; discussion 46–8. PMID 10446735.

[pmid21644844-9] Benjamin S, Doraiswamy PM (July 2011). „Review of the use of mirtazapine in the treatment of depression”. Expert Opinion on Pharmacotherapy 12 (10): 1623–32. DOI:10.1517/14656566.2011.585459. PMID 21644844.

[pmid10453798-10] Goodnick PJ, Puig A, DeVane CL, Freund BV (July 1999). „Mirtazapine in major depression with comorbid generalized anxiety disorder”. J Clin Psychiatry 60 (7): 446–8. DOI:10.4088/JCP.v60n0705. PMID 10453798.

[pmid19453203-11] 11,0 ^11,1 ^11,2 ^11,3 Croom KF, Perry CM, Plosker GL (2009). „Mirtazapine: a review of its use in major depression and other psychiatric disorders”. CNS Drugs 23 (5): 427–52. DOI:10.2165/00023210-200923050-00006. PMID 19453203.

[pmid16282842-12] Muehlbacher M, Nickel MK, Nickel C, et al. (December 2005). „Mirtazapine treatment of social phobia in women: a randomized, double-blind, placebo-controlled study”. Journal of Clinical Psychopharmacology 25 (6): 580–3. DOI:10.1097/01.jcp.0000186871.04984.8d. PMID 16282842. Arhivirano iz originala na datum 2015-11-27. Pristupljeno 2014-04-05.

[pmid11593084-13] Koran LM, Quirk T, Lorberbaum JP, Elliott M (October 2001). „Mirtazapine treatment of obsessive-compulsive disorder”. J Clin Psychopharmacol 21 (5): 537–9. DOI:10.1097/00004714-200110000-00016. PMID 11593084.

[pmid10440525-14] Carpenter LL, Leon Z, Yasmin S, Price LH (June 1999). „Clinical experience with mirtazapine in the treatment of panic disorder”. Ann Clin Psychiatry 11 (2): 81–6. DOI:10.3109/10401239909147053. PMID 10440525.

[pmid12090820-15] Carli V, Sarchiapone M, Camardese G, Romano L, DeRisio S (July 2002). „Mirtazapine in the treatment of panic disorder”. Arch. Gen. Psychiatry 59 (7): 661–2. DOI:10.1001/archpsyc.59.7.661. PMID 12090820.

[pmid18357426-16] Hrdlicka M, Beranova I, Zamecnikova R, Urbanek T (April 2008). „Mirtazapine in the treatment of adolescent anorexia nervosa. Case-control study”. European Child & Adolescent Psychiatry 17 (3): 187–9. DOI:10.1007/s00787-007-0670-8. PMID 18357426.

[pmid9917581-17] Hartmann PM (January 1999). „Mirtazapine: a newer antidepressant”. Am Fam Physician 59 (1): 159–61. PMID 9917581.

[pmid19374460-18] Jindal RD (2009). „Insomnia in patients with depression: some pathophysiological and treatment considerations”. CNS Drugs 23 (4): 309–29. PMID 19374460.

[pmid12404669-19] Nutt DJ (June 2002). „Tolerability and safety aspects of mirtazapine”. Human Psychopharmacology 17 Suppl 1: S37–41. DOI:10.1002/hup.388. PMID 12404669.

[pmid21602639-20] 20,0 ^20,1 Li TC, Shiah IS, Sun CJ, Tzang RF, Huang KC, Lee WK (June 2011). „Mirtazapine relieves post-electroconvulsive therapy headaches and nausea: a case series and review of the literature”. The Journal of ECT 27 (2): 165–7. DOI:10.1097/YCT.0b013e3181e63346. PMID 21602639. Arhivirano iz originala na datum 2013-05-09. Pristupljeno 2014-04-05.

[pmid17587360-21] Kast RE, Foley KF (July 2007). „Cancer chemotherapy and cachexia: mirtazapine and olanzapine are 5-HT3 antagonists with good antinausea effects”. Eur J Cancer Care (Engl) 16 (4): 351–4. DOI:10.1111/j.1365-2354.2006.00760.x. PMID 17587360.

[pmid12647431-22] Landowski J (2002). „[Mirtazapine--an antidepressant]” (Polish). Psychiatria Polska 36 (6 Suppl): 125–30. PMID 12647431.

[pmid18001374-23] Chinuck RS, Fortnum H, Baldwin DR (December 2007). „Appetite stimulants in cystic fibrosis: a systematic review”. Journal of Human Nutrition and Dietetics : the Official Journal of the British Dietetic Association 20 (6): 526–37. DOI:10.1111/j.1365-277X.2007.00824.x. PMID 18001374.

[pmid12647979-24] Davis MP, Khawam E, Pozuelo L, Lagman R (August 2002). „Management of symptoms associated with advanced cancer: olanzapine and mirtazapine. A World Health Organization project”. Expert Review of Anticancer Therapy 2 (4): 365–76. DOI:10.1586/14737140.2.4.365. PMID 12647979.

[pmid12509645-25] Twycross R, Greaves MW, Handwerker H, et al. (January 2003). „Itch: scratching more than the surface”. QJM : Monthly Journal of the Association of Physicians 96 (1): 7–26. DOI:10.1093/qjmed/hcg002. PMID 12509645.

[pmid16297004-26] Greaves MW (2005). „Itch in systemic disease: therapeutic options”. Dermatologic Therapy 18 (4): 323–7. DOI:10.1111/j.1529-8019.2005.00036.x. PMID 16297004.

[pmid15549531-27] Colombo B, Annovazzi PO, Comi G (October 2004). „Therapy of primary headaches: the role of antidepressants”. Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 25 Suppl 3: S171–5. DOI:10.1007/s10072-004-0280-x. PMID 15549531.

[pmid17073214-28] Tajti J, Almási J (June 2006). „[Effects of mirtazapine in patients with chronic tension-type headache. Literature review]” (Hungarian). Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakológiai Egyesület Lapja = Official Journal of the Hungarian Association of Psychopharmacology 8 (2): 67–72. PMID 17073214.

[1]